BloodPAC published generic analytical validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays to harmonize MRD (minimal residual disease) testing standards across platforms. The guidelines address limit of detection, limit of blank, accuracy, precision, robustness and sample stability — aiming to reduce variability in MRD analytical studies. Separately Veracyte outlined plans to launch TrueMRD for muscle‑invasive bladder cancer in H1 and previewed a pipeline of MRD studies across tumor types. Veracyte said it will pursue reimbursement and billing code strategies while leveraging whole‑transcriptome sequencing for additional diagnostic launches. Combined, the protocol release and Veracyte’s commercial timetable indicate coordination between consortium standards and near‑term product launches that may accelerate clinical adoption of MRD assays. Sources: BloodPAC publication in JCO Precision Oncology and Veracyte JP Morgan presentation.